VBIV תחזית צמיחת רווח נקי למניה לשנה הבאה VBI Vaccines, Inc.

VBI Vaccines Inc. relies on its proprietary drug development platform, generating steady revenue from the sale of hepatitis B treatments. Innovations in eVLP particles enable the creation of effective brain cancer vaccines with minimal side effects. The consensus for next year's earnings per share change, which this dynamic chart on GURU.Markets displays via the 77.80 metric, determines this level against the backdrop of the business's financial restructuring.
VBIV (VBI Vaccines Inc.): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This indicator measures the percentage change in expected earnings per share for the coming year, reflecting the analysts' consensus forecast on business growth rates. The trend in expected EPS growth for VBI Vaccines Inc. (VBIV) demonstrates the company's ability to overcome R&D costs and competition in the hepatitis B segment, determining the overall investment resilience of the asset.